ClinicalTrials.gg
RecruitingNCT07856797Radiesse ChinaUpdated Oct 29, 2026

A Study to Confirm Safety and Effectiveness of RADIESSE® Injectable Implant for the Correction of Moderate to Severe Nasolabial Folds

An interventional study of Subdermal Implant in Nasolabial Folds, sponsored by Merz North America, Inc.. Recruiting at 8 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by Merz North America, Inc. (part of Merz Pharma) · Not applicable, Interventional, and Treatment

Updated Oct 29, 2026Now RecruitingFirst site in China+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
163
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to confirm the long-term safety, effectiveness, and degradation profile of RADIESSE® Injectable Implant for the correction of moderate to severe nasolabial folds (NLFs) in Chinese adults. Eligible participants will receive treatment with RADIESSE® Injectable Implant in both NLFs and may receive an optional touch-up treatment at Month 1 at investigator's discretion. Participants will be followed for up to 24 months after last treatment.

02

Conditions studied

  • Nasolabial Folds
03

In context

Lead sponsor

Merz North America, Inc. is the lead sponsor of 53 studies on the registry; 1 is open to participants now.

Of its 20 completed or terminated interventional studies of FDA-regulated products, 19 (95%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • WSRS score of 3 (moderate) or 4 (severe) in both right and left NLFs, as determined live by the treating investigator. The WSRS score for the right and the left NLF does not have to be equal.
  • Willing to abstain from other aesthetic treatments in the NLF area during study participation.

Exclusion criteria

Exclusion Criteria:

  • Prior dermal filler or implant material detectable in the NLF area by ultrasound.
  • Active infection or acute inflammation at treatment sites.
  • Hyaluronic Acid or collagen filler treatment in NLFs within 12 months.
  • CaHA or Poly L-Lactic Acid filler treatment in NLFs within 24 months.
  • Recent facial dermal therapies in the midface region within the past 6 months.
  • Prior facial surgery or implants that could interfere with assessments.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
163 participants (estimated)

Study arms

  • Experimental
    RADIESSE® Injectable Implant

    Participants will receive a single injection of RADIESSE® administered to both NLFs on Day 1. Participants may receive an optional touch-up injection at Month 1 following the initial treatment at investigator's discretion. RADIESSE® will be administered according to the current product labelling and instruction for use.

    Device: Subdermal Implant

Interventions

  • DeviceSubdermal Implant

    Participants will receive treatment with RADIESSE® Injectable Implant.

    Also known as: Calcium Hydroxylapatite (CaHA)

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving at Least a 1-point Improvement in Both NLFs From Baseline to Month 6 after Last Treatment on the Wrinkle Severity Rating Scale (WSRS), as Assessed Live by the Treating Investigator

    Severity of the NLFs was assessed and measured using the 5-point WSRS, where 1=absent and 5=extreme. A lower score indicates better outcome.

    Time frame: At Month 6 after last treatment

Secondary outcomes

  1. Percentage of Participants Achieving Improvement (Score of 1, 2, 3) on the Investigator Global Aesthetic Improvement Scale (iGAIS) at Month 6 After Last Treatment, as Assessed Live by the Treating Investigator

    The iGAIS is an assessment grading scale where the treating investigator describes the degree of improvement in facial appearance according to the GAIS, a 5-point scale ranging from 'Very Much Improved' (1) to 'Worse' (5). The investigator will be asked to rate the NLFs and select the rating that best applies when asked "What is the overall impression of aesthetic change of the participants NLFs due to treatment, compared to the pretreatment photograph". Improvement is defined as a rating of +1, +2, or +3. The higher the iGAIS score, the greater the improvement.

    Time frame: At Month 6 after last treatment

  2. Percentage of Participants Achieving Improvement (Score of 1, 2, 3) on the Participant Global Aesthetic Improvement Scale (pGAIS) at Month 6 After Last Treatment, as Assessed Live by Participant

    The pGAIS is a self-assessment grading scale where the participant independently describes the degree of improvement in facial appearance according to the GAIS, a 5-point scale ranging from 'Very Much Improved' (1) to 'Worse' (5). Participants will be asked to rate the NLFs and select the rating that best applies when asked "What is the overall impression of aesthetic change of your NLFs due to treatment, compared to the pretreatment photograph?" Improvement is defined as a rating of +1, +2, or +3. The higher the pGAIS score, the greater the improvement.

    Time frame: At Month 6 after last treatment

07

Study locations

8 of 8 sites recruiting
  • Merz Investigative Site
    Beijing, 100034, China
    Recruiting
  • Merz Investigative Site
    Changde, 415000, China
    Recruiting
  • Merz Investigative Site
    Chengdu, 610021, China
    Recruiting
  • Merz Investigative Site
    Gaozhou, 525200, China
    Recruiting
  • Merz Investigative Site
    Hangzhou, 311200, China
    Recruiting
  • Merz Investigative Site
    Nanjing, 210029, China
    Recruiting
  • Merz Investigative Site
    Xianyang, 712099, China
    Recruiting
  • Merz Investigative Site
    Yibin, 644000, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2026 (actual). Primary completion is estimated for Aug 2027, 10 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2026
First posted
Oct 5, 2026
StartActual
Oct 27, 2026
Primary completionEst.
Aug 2027
CompletionEst.
Feb 2029
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 29, 2026
Sites
8 sites added — first site in China
Show 8 added (8 China)
  • Merz Investigative Site · Beijing, China
  • Merz Investigative Site · Changde, China
  • Merz Investigative Site · Chengdu, China
  • Merz Investigative Site · Gaozhou, China
  • Merz Investigative Site · Hangzhou, China
  • Merz Investigative Site · Nanjing, China
  • Merz Investigative Site · Xianyang, China
  • Merz Investigative Site · Yibin, China
Oct 29, 2026
Registered
First appeared on the registry
Oct 5, 2026
Show all 2 updates
  1. Oct 29, 2026
    Not yet recruiting→Recruiting
    8 sites added — first site in China
    Show 8 added (8 China)
    • Merz Investigative Site · Beijing, China
    • Merz Investigative Site · Changde, China
    • Merz Investigative Site · Chengdu, China
    • Merz Investigative Site · Gaozhou, China
    • Merz Investigative Site · Hangzhou, China
    • Merz Investigative Site · Nanjing, China
    • Merz Investigative Site · Xianyang, China
    • Merz Investigative Site · Yibin, China
    + 2 other changes: verification date and date precision
  2. Oct 5, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07856797
Responsible party
Sponsor
First posted
Oct 5, 2026
Start date
Oct 27, 2026
Primary completion
Aug 2027 (estimated)
Completion
Feb 2029 (estimated)
Last update
Oct 29, 2026

Study contacts

Public Disclosure Manager
Contact
Aesthetic.Trials@merz.com
+1 984-301-3095
Merz Medical Expert
study director · Merz North America, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion